Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clozapine once-daily versus twice-daily pharmacokinetics study
2017-004834-26Phase 4Active
- Sponsor
- Albert Schweitzer Hospital
- Start
- Mar 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of clozapine in schizophrenia and Schizophrenia Spectrum Disorders (SSD) (2 arms), sponsored by Albert Schweitzer Hospital. Primary endpoints: Total clozapine plasma concentration, Unbound clozapine plasma concentration and 5 more. Started Mar 2018; status: active.
02
Drugs
clozapine
03
Conditions
schizophreniaSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on 2017-004834-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004834-26.